ALK and non-small cell lung carcinoma: Specifically, while phase III studies have shown that crizotinib improves PFS compared to chemotherapy in previously treated NSCLC patients with ALK-positive disease (HR = 0.49 95% CI: 0.37–0.64, p < 0.001), only 65% of patients were shown to respond to therapy (67).